{
  "id": 9551425,
  "title": "Marea to present MAR001 trial data at AHA conference",
  "url": "https://urgent.news/2026/09/24/marea-to-present-mar001-trial-data-at-aha-conference",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-24T12:12:33.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/company-news/marea-to-present-mar001-trial-data-at-aha-conference-93CH-4915278"
  },
  "original_language": "en",
  "account": "Marea Therapeutics will showcase Phase 2b trial results for MAR001 at the American Heart Association meeting in November 2026. The monoclonal antibody targets ANGPTL4 to lower triglycerides and enhance lipoprotein lipase activity. MAR001 has already progressed through Phase 1 and 2a development stages.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}